KRYS - クリスタル・バイオテック （Krystal Biotech Inc.） クリスタル・バイオテックKRYSのチャート
KRYSの企業情報
| symbol | KRYS |
|---|---|
| 会社名 | Krystal Biotech Inc （クリスタル・バイオテック） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Krystal Biotech Inc. is a gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform or STAR-D platform that consists of a patent pending engineered viral vector based on herpes simplex virus 1 or HSV-1 and skin-optimized gene transfer technology to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Company''s KB103 is in preclinical development to treat dystrophic epidermolysis bullosa or DEB a rare and severe genetic disease. The Company''s KB104 is to treat Netherton Syndrome a severe form of ichthyosis which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation itchiness and dehydration. クリスタル・バイオテックは米国のバイオ医薬品企業。主に皮膚疾患に対する遺伝子治療の開発・商業化に従事する。同社はHSV-1に基づくウィルスベクタ―と皮膚最適化遺伝子導入技術プラットフォ―ム「STAR-D」を開発。重度の遺伝病であるジストロフィ―性表皮水疱症に対する遺伝子治療「KB-103」を開発する。本社所在地はペンシルベニア州ピッツバ―グ。 Krystal Biotech, Inc. is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. |
| 本社所在地 | 2100 Wharton Street Suite 701 Pittsburgh PA 15203 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 412-586-5830 |
| 設立年月日 | 42339 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2017年 |
| 従業員数 | － |
| url | www.krystalbio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/krys |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -8.25600 |
| 終値（lastsale） | 15.51 |
| 時価総額（marketcap） | 170282987.16 |
| 時価総額 | 時価総額（百万ドル） 234.93030 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 189.48030 |
| 当期純利益 | 当期純利益（百万ドル） -11.09200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Krystal Biotech Inc revenues was not reported. Net loss increased from $1.3M to $4.4M. Higher net loss reflects Research and Development - Balancing increase from $698K to $2.9M (expense) General and Administrative - Balancing increase from $347K to $1.6M (expense) Stock-based Compensation in R&D increase of 82% to $122K (expense). |
KRYSのテクニカル分析
KRYSのニュース
Krystal Biotech to Present at 5th Annual Evercore ISI HealthCONx Conference 2022/11/23 12:00:00 GlobeNewswire
PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that the Company will participate in the Evercore ISI 5 th Annual HealthCONx Conference, which is taking place virtually from November 29-December 1.
Krystal Biotech gene-based wrinkle therapy demonstrates nine month durability (KRYS) 2022/11/17 14:19:56 Seeking Alpha
Jeune Aesthetics said that phase 1 data showed that KB301, a gene-based treatment designed to address the biology of aging skin to treat wrinkles, demonstrated durability over nine months.
Krystal Biotech''s Subsidiary Posts Durability Data For Fine Line, Wrinkles 2022/11/17 14:07:51 Benzinga
Krystal Biotech Inc''s (NASDAQ: KRYS ) subsidiary Jeune Aesthetics Inc , announced nine-month durability of effect in the extension cohort of the PEARL-1 study of KB301 to address the underlying biology of aging skin for improvement of fine lines and wrinkles. Ten subjects from the PEARL-1 efficacy cohort were enrolled in the PEARL-1 extension cohort, an open-label study to assess the duration of … Full story available on Benzinga.com
5 Most Promising Gene Therapy Companies to Watch 2022/11/14 19:29:59 Insider Monkey
In this piece, we will take a look at the five most promising gene therapy companies to watch. For more companies, take a look at 10 Most Promising Gene Therapy Companies to Watch. 5. Krystal Biotech, Inc. (NASDAQ:KRYS) Market Capitalization as of November 12, 2022: $1.97 billion Krystal Biotech, Inc. (NASDAQ:KRYS) develops treatments for rare […]
Krystal Biotech Needs to Feed the Goldfish in 2023 2022/11/07 17:29:08 The Street
Development delays across the pipeline risks losing interest on Wall Street, which has the attention span of a goldfish.
FDA Accepts Krystal Biotech''s Filing For Genetic Skin Disorder Candidate Under Priority Review 2022/08/18 21:42:38 Benzinga
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS ) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17, 2023. The Biologics License Application (BLA) submission for B-VEC is supported by the clinical data readouts from the GEM-3 and … Full story available on Benzinga.com
FDA accepts Krystal Biotech''s biologics license application for genetic skin disorder DEB 2022/08/18 21:26:00 Seeking Alpha
Krystal Biotech (KRYS) on Thursday said the U.S. FDA had accepted its biologics license application for its gene therapy B-VEC for the treatment of dystrophic epidermolysis…
Krystal Biotech GAAP EPS of -$1.10 misses by $0.07 (NASDAQ:KRYS) 2022/08/08 12:39:00 Seeking Alpha
Krystal Biotech press release (KRYS): Q2 GAAP EPS of -$1.10 misses by $0.07.Strong balance sheet, closing the quarter with $438.5 million in cash, cash equivalents and investments.
KRYSTAL BIOTECH, INC. – 10-Q – MANAGEMENT''S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 2022/08/08 11:54:10 InsuranceNewsNet
The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10- Q and with the audited financial statements and the related notes included in our Annual…
Krystal Biotech, Inc. Misses Q2 EPS by 9c By Investing.com 2022/08/08 11:21:01 Investing.com
Krystal Biotech, Inc. Misses Q2 EPS by 9c
FDA Accepts Krystal Biotech''s Filing For Genetic Skin Disorder Candidate Under Priority Review 2022/08/18 21:42:38 Benzinga
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS ) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17, 2023. The Biologics License Application (BLA) submission for B-VEC is supported by the clinical data readouts from the GEM-3 and … Full story available on Benzinga.com
FDA accepts Krystal Biotech''s biologics license application for genetic skin disorder DEB 2022/08/18 21:26:00 Seeking Alpha
Krystal Biotech (KRYS) on Thursday said the U.S. FDA had accepted its biologics license application for its gene therapy B-VEC for the treatment of dystrophic epidermolysis…
Krystal Biotech GAAP EPS of -$1.10 misses by $0.07 (NASDAQ:KRYS) 2022/08/08 12:39:00 Seeking Alpha
Krystal Biotech press release (KRYS): Q2 GAAP EPS of -$1.10 misses by $0.07.Strong balance sheet, closing the quarter with $438.5 million in cash, cash equivalents and investments.
KRYSTAL BIOTECH, INC. – 10-Q – MANAGEMENT''S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 2022/08/08 11:54:10 InsuranceNewsNet
The following discussion and analysis of our financial condition and results of operations should be read together with the unaudited condensed consolidated financial statements and related notes included in Item 1 of Part I of this Quarterly Report on Form 10- Q and with the audited financial statements and the related notes included in our Annual…